NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
12/12/2023
Back to search
Official data from USPTO
ELIXIRGEN THERAPEUTICS
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
ELIXIRGEN THERAPEUTICS
ST13
US500000097976453Class
5, 42
Filing
97976453
Registration
7244784
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
29
Latest update
12/12/2023
Trademark type
Word
Nice classes
5, 42
Filing date
12/01/2021
Registration date
12/12/2023
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
12/12/2023
Last transaction
12/12/2023
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use
First use anywhere
07/06/2023
First use in commerce
07/06/2023
Drawing code
4
Owner type
03
Owner location
Baltimore, MD
Examiner
NUNLEY, CHRISTOPHER
Law office
L40
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
Elixirgen Therapeutics, Inc.
Representatives
Leonard D. Bowersox KILYK & BOWERSOX, P.L.L.C.
Technical classification
Nice Classes
Class 5Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical drugs for the treatment of infectious diseasescanceraging-related diseases; chemical preparations for medicinal purposesfor the treatment of infectious diseasescanceraging-related diseases; chemical preparations for pharmaceutical purposesfor the treatment of infectious diseasescanceraging-related diseases; preparations of organisms for medical purposesfor the treatment of infectious diseasescanceraging-related diseases
Class 42
Research and development of vaccines and medicines; testing of pharmaceuticals; research in the field of pharmaceuticals
Publications
History of USPTO decisions and trademark events.
29 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
12/12/2023
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
11/07/2023
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
11/06/2023
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
09/13/2023
SUPC
STATEMENT OF USE PROCESSING COMPLETE
09/12/2023
EX1G
SOU EXTENSION 1 GRANTED
09/12/2023
DPCC
DIVISIONAL PROCESSING COMPLETE
09/12/2023
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
08/28/2023
IUAF
USE AMENDMENT FILED
08/22/2023
EXT1
SOU EXTENSION 1 FILED
08/22/2023
DRRR
DIVISIONAL REQUEST RECEIVED
08/22/2023
EEXT
SOU TEAS EXTENSION RECEIVED
08/22/2023
EISU
TEAS STATEMENT OF USE RECEIVED
08/22/2023
ERTD
TEAS REQUEST TO DIVIDE RECEIVED
08/22/2023
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
04/25/2023
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
02/28/2023
PUBO
PUBLISHED FOR OPPOSITION
02/28/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
02/08/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
01/20/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
01/19/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
01/19/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
01/19/2023
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
09/19/2022
GNRT
NON-FINAL ACTION E-MAILED
09/19/2022
CNRT
NON-FINAL ACTION WRITTEN
09/19/2022
DOCK
ASSIGNED TO EXAMINER
09/10/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
12/06/2021
NWAP
NEW APPLICATION ENTERED
12/04/2021
Continuous trademark protection
Get notified about every new filing that threatens ELIXIRGEN THERAPEUTICS or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.